PurposeAdding atumour bed boost to whole-breast irradiation in breast-conserving therapy reduces local recurrence rates. The purpose of the present study was to investigate whether the boost technique influences the magnitude of the effect.MethodsPatients treated with breast-conserving therapy for invasive breast cancer between 2000 and 2007 were included in the analysis. Three groups were considered according to the applied boost technique: electrons, brachytherapy or photons. The endpoints were local recurrence and any recurrence. Cox regression models were used and correction for the confounders in the association between boost technique and outcome was performed using multivariable models.Results1879 tumours were included in the analysi...
Background: Since the introduction of breast-conserving treatment, various radiation doses after lum...
PURPOSE: To investigate the impact of the boost dose to the primary tumour bed in the framework of b...
Between December 1981 and December 1988, 329 consecutive patients with stage I and II breast cancers...
PurposeAdding atumour bed boost to whole-breast irradiation in breast-conserving therapy reduces loc...
BACKGROUND AND PURPOSE: The EORTC Trial 22881/10882 investigating the role of a boost dose in breast...
SummaryIn women with early stage breast cancer brachytherapy (BR) boost allows increase of the dose ...
In women with early stage breast cancer brachytherapy (BR) boost allows increase of the dose adminis...
PURPOSE: To investigate the long-term impact of a boost radiation dose of 16 Gy on local control, fi...
IMPORTANCE: The use of a radiotherapy (RT) boost to the tumor bed after whole-breast RT (WBRT) for d...
BACKGROUND: Radiotherapy prevents local recurrence of breast cancer after breast-conserving surgery....
Objective: to compare cosmetic result of two techniques of boost delivery to the tumor bed after bre...
PURPOSE: To determine whether a boost to the tumor bed after breast-conserving surgery (BCS) and ra...
BACKGROUND: Since the introduction of breast-conserving treatment, various radiation doses after lum...
BACKGROUND In a phase 3, randomised, non-inferiority trial, accelerated partial breast irradiatio...
For women who had breast-conserving surgery (BCS), brachytherapy can be used along with external bea...
Background: Since the introduction of breast-conserving treatment, various radiation doses after lum...
PURPOSE: To investigate the impact of the boost dose to the primary tumour bed in the framework of b...
Between December 1981 and December 1988, 329 consecutive patients with stage I and II breast cancers...
PurposeAdding atumour bed boost to whole-breast irradiation in breast-conserving therapy reduces loc...
BACKGROUND AND PURPOSE: The EORTC Trial 22881/10882 investigating the role of a boost dose in breast...
SummaryIn women with early stage breast cancer brachytherapy (BR) boost allows increase of the dose ...
In women with early stage breast cancer brachytherapy (BR) boost allows increase of the dose adminis...
PURPOSE: To investigate the long-term impact of a boost radiation dose of 16 Gy on local control, fi...
IMPORTANCE: The use of a radiotherapy (RT) boost to the tumor bed after whole-breast RT (WBRT) for d...
BACKGROUND: Radiotherapy prevents local recurrence of breast cancer after breast-conserving surgery....
Objective: to compare cosmetic result of two techniques of boost delivery to the tumor bed after bre...
PURPOSE: To determine whether a boost to the tumor bed after breast-conserving surgery (BCS) and ra...
BACKGROUND: Since the introduction of breast-conserving treatment, various radiation doses after lum...
BACKGROUND In a phase 3, randomised, non-inferiority trial, accelerated partial breast irradiatio...
For women who had breast-conserving surgery (BCS), brachytherapy can be used along with external bea...
Background: Since the introduction of breast-conserving treatment, various radiation doses after lum...
PURPOSE: To investigate the impact of the boost dose to the primary tumour bed in the framework of b...
Between December 1981 and December 1988, 329 consecutive patients with stage I and II breast cancers...